MedinCell S.A. (MEDCL.PA)
EUR 16.8
(5.53%)
EUR 16.8
(5.53%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -20.04 Million EUR | 28.88% |
| 2022 | -30.17 Million EUR | 1.72% |
| 2021 | -22.94 Million EUR | -50.53% |
| 2020 | -17.69 Million EUR | 16.6% |
| 2019 | -18.36 Million EUR | -39.35% |
| 2018 | -15.22 Million EUR | -137.61% |
| 2017 | -6.47 Million EUR | -193.18% |
| 2016 | -3.03 Million EUR | -377.28% |
| 2015 | 788 Thousand EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 FY | - EUR | 28.88% |
| 2023 Q2 | -9.29 Million EUR | 0.0% |
| 2023 Q4 | -11.55 Million EUR | 0.0% |
| 2022 Q2 | -12.52 Million EUR | 0.0% |
| 2022 Q4 | -13.65 Million EUR | 0.0% |
| 2022 FY | - EUR | 1.72% |
| 2021 Q2 | -13.05 Million EUR | 0.0% |
| 2021 Q4 | -13.57 Million EUR | 0.0% |
| 2021 FY | - EUR | -50.53% |
| 2020 FY | - EUR | 16.6% |
| 2020 Q4 | -8.48 Million EUR | 0.0% |
| 2020 Q2 | -9.22 Million EUR | 0.0% |
| 2019 Q4 | -11.62 Million EUR | 0.0% |
| 2019 FY | - EUR | -39.35% |
| 2019 Q2 | -9.48 Million EUR | 0.0% |
| 2018 Q4 | -8.65 Million EUR | -100.0% |
| 2018 Q3 | -4.32 Million EUR | 30.79% |
| 2018 Q1 | -3.12 Million EUR | -16.35% |
| 2018 Q2 | -6.25 Million EUR | -100.0% |
| 2018 FY | - EUR | -137.61% |
| 2017 Q2 | -3.78 Million EUR | -100.0% |
| 2017 Q4 | -2.68 Million EUR | -100.0% |
| 2017 FY | - EUR | -193.18% |
| 2017 Q3 | -1.34 Million EUR | 64.5% |
| 2017 Q1 | -1.89 Million EUR | 0.0% |
| 2016 FY | - EUR | -377.28% |
| 2015 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.29 Million EUR | -509.301% |
| ABIVAX Société Anonyme | -133.2 Million EUR | 84.951% |
| Adocia SA | -22.73 Million EUR | 11.816% |
| Aelis Farma SA | -6.34 Million EUR | -215.834% |
| Biophytis S.A. | -13.8 Million EUR | -45.219% |
| Advicenne S.A. | -6.24 Million EUR | -221.044% |
| genOway Société anonyme | 6.35 Million EUR | 415.648% |
| IntegraGen SA | -52.5 Thousand EUR | -38080.675% |
| Medesis Pharma S.A. | -3.84 Million EUR | -421.368% |
| Neovacs S.A. | -8.44 Million EUR | -137.244% |
| NFL Biosciences SA | -4.04 Million EUR | -395.048% |
| Plant Advanced Technologies SA | 72.53 Thousand EUR | 27738.219% |
| Quantum Genomics Société Anonyme | -2.87 Million EUR | -597.621% |
| Sensorion SA | -22.31 Million EUR | 10.163% |
| Theranexus Société Anonyme | -7.38 Million EUR | -171.36% |
| TME Pharma N.V. | -5.07 Million EUR | -295.229% |
| Valbiotis SA | -6.95 Million EUR | -188.224% |
| TheraVet SA | -517.33 Thousand EUR | -3774.851% |
| Valerio Therapeutics Société anonyme | -18.91 Million EUR | -5.974% |
| argenx SE | -199.5 Million EUR | 89.952% |
| BioSenic S.A. | -6.79 Million EUR | -194.968% |
| Celyad Oncology SA | -7.76 Million EUR | -158.225% |
| DBV Technologies S.A. | -79.53 Million EUR | 74.795% |
| Galapagos NV | 51.03 Million EUR | 139.277% |
| Genfit S.A. | -28.05 Million EUR | 28.537% |
| GeNeuro SA | -14.31 Million EUR | -40.009% |
| Hyloris Pharmaceuticals SA | -14.98 Million EUR | -33.818% |
| Innate Pharma S.A. | -7.57 Million EUR | -164.529% |
| Inventiva S.A. | -101.84 Million EUR | 80.318% |
| MaaT Pharma SA | -19.74 Million EUR | -1.55% |
| Nanobiotix S.A. | -34.01 Million EUR | 41.074% |
| Onward Medical N.V. | -35.23 Million EUR | 43.106% |
| Oryzon Genomics S.A. | -4.43 Million EUR | -352.163% |
| OSE Immunotherapeutics SA | -23.26 Million EUR | 13.84% |
| Oxurion NV | -16.72 Million EUR | -19.828% |
| Pharming Group N.V. | 4.98 Million EUR | 502.452% |
| Poxel S.A. | -12.17 Million EUR | -64.595% |
| GenSight Biologics S.A. | -21.73 Million EUR | 7.75% |
| Transgene SA | -27.02 Million EUR | 25.821% |
| Financière de Tubize SA | 184.57 Thousand EUR | 10960.861% |
| UCB SA | 1.26 Billion EUR | 101.58% |
| Valneva SE | -64.51 Million EUR | 68.929% |
| Vivoryon Therapeutics N.V. | -28.35 Million EUR | 29.298% |